Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis - PubMed
5 hours ago
- #immune checkpoint inhibitors
- #cervical cancer
- #meta-analysis
- Adding immune checkpoint inhibitors (ICIs) to standard chemotherapy (CT) or chemoradiotherapy (CRT) improves progression-free survival (PFS) and overall survival (OS) in advanced or recurrent cervical cancer (CC).
- The benefits of ICIs are particularly pronounced in patients with a PD-L1 combined positive score (CPS) ≥ 1, while those with CPS <1 do not show significant improvement.
- While ICIs do not increase the risk of all-cause adverse events (AEs) of any grade, they are associated with a higher incidence of grade 3-5 AEs.
- Trial sequential analysis (TSA) confirmed the robustness of the findings for PFS and OS, but the objective response rate (ORR) showed limited robustness.
- The study highlights the potential of ICIs to enhance immune-mediated tumor control, offering a promising therapeutic option for selected patient populations, but emphasizes the need for vigilant toxicity monitoring.